Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
about
VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sproutsSemaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effectCritical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancersAngiogenesis in metastatic colorectal cancer and the benefits of targeted therapyDrugs derived from phage display: from candidate identification to clinical practiceEvolution of ramucirumab in the treatment of cancer - A review of literatureBlood vessels as targets in tumor therapyA humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft modelsMolecular imaging of vessels in mouse models of disease.Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.The VEGF family in cancer and antibody-based strategies for their inhibition.Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.Molecular targeting to treat gastric cancer.Ramucirumab: preclinical research and clinical development.A novel rabbit immunospot array assay on a chip allows for the rapid generation of rabbit monoclonal antibodies with high affinityAnti-angiogenic therapies for advanced esophago-gastric cancerInterleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model.Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy.TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis.A high-affinity human/mouse cross-reactive monoclonal antibody, specific for VEGFR-2 linear and conformational epitopes.Animal models of acute myelogenous leukaemia - development, application and future perspectives.Survival of chronic lymphocytic leukemia cells: CD40L and the vascular endothelial growth factor (VEGF) connection.Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody.U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biologyVEGF/VEGFR signalling as a target for inhibiting angiogenesis.Monoclonal antibody-based therapeutics for leukemia.Angiogenesis in Liquid Tumors: An In Vitro Assay for Leukemic-Cell-Induced Bone Marrow Angiogenesis.Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.Avian leukosis virus subgroup J induces VEGF expression via NF-κB/PI3K-dependent IL-6 production.Ramucirumab (IMC-1121B): a novel attack on angiogenesis.Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2.Emerging therapeutic targets in schwannomas and other merlin-deficient tumors.Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.Mechanism and Function of Angiogenin in Hematopoietic Malignancy.Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.Population Pharmacokinetic Meta-Analysis of Ramucirumab in Cancer Patients.
P2860
Q24302234-EACAABEC-10C4-4E1F-8B96-3884F12D3348Q24564247-1F3DC660-4E8C-4F56-8496-524C00526AE2Q26801289-4E61DE2E-0162-4B8C-BEF4-E3835A34B064Q26853604-BB53B701-3DDF-4F8F-B640-910B971E0715Q27007101-D8119A43-2129-4FD8-8C87-5FF2445A118BQ28276412-095FC204-F2C7-4644-9611-7317C01DDBEFQ28590737-48E0A0EA-C79C-4A77-9321-A459417E5BBFQ28749085-FD0CB8B2-48AB-4B73-89A4-5CEC6858A781Q30481645-2ECE8D8D-BC88-4E66-ADBD-1B88E3E87F6CQ33576327-0CA014B3-2139-4693-B0F5-92497EBB6F8EQ33710574-F9D74C53-0253-49DC-806E-0E6143B87AEDQ33733437-7D9DBCF8-E626-42D0-8F6E-C531FE09E713Q34078666-55112B31-FEE3-40C8-97BF-17D7575C7DA2Q34326593-2AB6FF56-7F9D-4314-A742-994238212D21Q34446310-F9076807-5933-419E-BA23-6AB2CB4B70D5Q34540651-C08F85B9-751C-432E-AD81-58F4C936BCB2Q34686222-9DE92A96-55ED-4078-8933-144BDF32C4F4Q34770006-23409FF8-7CA6-417D-820A-950ADD7A7532Q35176443-FEC17EDC-2A34-4C43-976B-A546B6DF1B22Q35622461-F545E9C1-667D-442E-A2BF-321F6F4990A4Q35828124-06C4205C-8687-4439-8FE6-822A1618A1C2Q36066980-BBDD8181-0E18-4B34-A85C-9503F14829BAQ36110555-C7177F24-EF5C-4960-B468-E4C09D13E4A2Q36453638-6F5EAB9E-CF4A-4029-AFB4-63A7817B27BCQ36478734-673C462B-304B-4097-AE8F-56737C46D18CQ36645343-F0488E35-8C5D-4F30-B2C4-44013B3FA7D5Q36677407-8D40C052-086A-41FA-B49D-460C99B8F46DQ36739759-58581FFC-2218-408A-A05C-9F5FF028008FQ36959804-A88924CF-22F0-4B1F-A6A7-A23BAAC1F7A2Q37071261-626BB6FB-3D94-4537-9F24-9B7FA5CC9BAEQ37513843-170E84A3-E5F9-4200-943B-5B50A4B64940Q37696994-8B0A50E2-C4F7-4D93-AA50-9AE78C054E99Q37771954-3741CF11-01B9-49E4-85B7-D49DE6163F33Q37827451-4ABEFF52-343F-4D5E-8D56-A6E7F0B99322Q37885731-940CDAC0-2CB4-4907-9356-032358103525Q38166329-931ABA27-0BC9-4969-A4C2-53538044FDA2Q38333228-4F663A71-AE1F-4276-A90C-5146F455F70BQ38366707-B1776ECB-E42F-499D-BBC0-E08B57191393Q38578404-B1B5448B-3BF5-4556-A8FC-A502644F1144Q38612237-3D52BFF5-BA7F-4584-A8C2-503485B31C08
P2860
Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Inhibition of human leukemia i ...... inity and biological activity.
@ast
Inhibition of human leukemia i ...... inity and biological activity.
@en
type
label
Inhibition of human leukemia i ...... inity and biological activity.
@ast
Inhibition of human leukemia i ...... inity and biological activity.
@en
prefLabel
Inhibition of human leukemia i ...... inity and biological activity.
@ast
Inhibition of human leukemia i ...... inity and biological activity.
@en
P2093
P921
P356
P1433
P1476
Inhibition of human leukemia i ...... inity and biological activity.
@en
P2093
Friedrich M
P2888
P304
P356
10.1038/SJ.LEU.2402831
P577
2003-03-01T00:00:00Z
P5875
P6179
1038120105